Cardurion Pharmaceuticals Inc. raised $260m in series B venture capital to fund ongoing Phase II clinical trials in heart failure and a rare genetic arrhythmic disease for its two lead drug candidates as well as in-house discovery work and external sourcing of novel drug candidates. The company’s clinical-stage programs came from outside sources, and it continues to search for first-in-class cardiovascular disease medicines at a time when dealmaking in the cardiometabolic space is getting increasingly competitive.
Key Takeaways
-
Cardurion raised $260m in series B venture capital to fund Phase II clinical trials of its PDE9 inhibitor in heart failure and its CaMKII inhibitor in a rare genetic arrhythmic disease.
-
Both first-in-class drug candidates were externally sourced – the PDE9 asset from Imara Inc. and the CaMKII inhibitor from Takeda – and the company continues to seek outside assets
“No question, there is renewed interest in the space,” Cardurion CEO Peter Lawrence told Scrip. But while cardiovascular drug development largely was the domain of big pharma companies in the past, the success of biotech firms like MyoKardia, Inc. and Cytokinetics, Inc
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
